Life Scientific Azoxystrobin

Hauptinformation

  • Handelsname:
  • Life Scientific Azoxystrobin
  • Darreichungsform:
  • SC Suspensionskonzentrat
  • Verwenden für:
  • Pflanzen
  • Art der Medizin:
  • Agrochemisch

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Life Scientific Azoxystrobin
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Fungizid

Weitere Informationen

Status

  • Quelle:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Zulassungsnummer:
  • B-5421
  • Letzte Änderung:
  • 15-11-2018

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Handelsbezeichnung: Life Scientific

Azoxystrobin (Parallelimport)

Pflanzenschutzmittelverzeichnis (Stand: 06.11.2018)

Produktkategorie:

Ausl. Bewilligungsinhaber:

Eidg. Zulassungsnummer:

Fungizid

Life Sciences Ltd

B-5421

Stoff(e):

Gehalt:

Formulierungscode:

Wirkstoff: Azoxystrobin 22.8 % 250 g/l

SC Suspensionskonzentrat

Anwendungen

A

Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

B Erdbeere

Echter Mehltau der Erdbeere

Teilwirkung:

Graufäule (Botrytis cinerea)

Konzentration: 0.1 %

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

1, 2, 3

B Ribes Arten

Echter Mehltau der Ribes-Arten

Konzentration: 0.1 %

Aufwandmenge: 1 l/ha

Wartefrist: 3 Woche(n)

2, 4, 5, 6

Rote Johannisbeere

Schwarze

Johannisbeere

Stachelbeere

Mondscheinigkeit

Konzentration: 0.1 %

Aufwandmenge: 1 l/ha

Wartefrist: 3 Woche(n)

2, 4, 5, 6

B Rubus Arten

Teilwirkung:

Rutenkrankheiten der Brombeere

Rutenkrankheiten der Himbeere

Konzentration: 0.1 %

Aufwandmenge: 1 l/ha

Wartefrist: 3 Woche(n)

2, 5, 6, 7, 8

Aprikose

Pfirsich / Nektarine

Pflaume

Zwetschge

Blüten- und Zweigdürre

Schrotschuss

Konzentration: 0.1 %

Aufwandmenge: 1.6 l/ha

Wartefrist: 3 Woche(n)

Anwendung: Bis

spätestens BBCH 70.

2, 6, 9, 10

O Kirsche

Bitterfäule der Kirsche

Blüten- und Zweigdürre

Schrotschuss

Konzentration: 0.1 %

Aufwandmenge: 1.6 l/ha

Wartefrist: 3 Woche(n)

Anwendung: Bis

spätestens BBCH 70.

2, 6, 9, 10

G Artischocken

Falscher Mehltau der Artischocke

Aufwandmenge: 1 l/ha

Wartefrist: 7 Tage

2, 11, 12

A

Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

Asia-Salate

(Brassicaceae)

Blattfleckenpilze

Aufwandmenge: 1 l/ha

Wartefrist: 7 Tage

Anwendung: Ab Stadium

BBCH 13.

2, 12, 13

Blattkohle

Blumenkohle

Kopfkohle

Rosenkohl

Blattfleckenpilze

Echter Mehltau der Kreuzblütler

Falscher Mehltau der

Kreuzblütengewächse

Ringflecken des Kohls

Weisser Rost

Teilwirkung:

Graufäule (Botrytis cinerea)

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 14

G Bohnen mit Hülsen

Braunfleckenkrankheit

Brennfleckenkrankheit der Bohne

Falscher Mehltau der Bohne

Sclerotinia-Fäule

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 14

G Chicorée

Echter Mehltau der Asteraceen

Samtfleckenkrankheit

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 11, 12

G Erbsen ohne Hülsen

Brennfleckenkrankheit der Erbse

Falscher Mehltau der Erbse

Graufäule (Botrytis cinerea)

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 11, 15

Gurken

Kürbisse mit

geniessbarer Schale

Melonen

Anthraknose der Kürbisgewächse

Krätze der Kürbisgewächse

Konzentration: 0.08 %

Aufwandmenge: 0.8 l/ha

Wartefrist: 3 Tage

2, 11, 12

Gewächshaus:

Gurken

Gewächshaus:

Kürbisse mit

geniessbarer Schale

Gewächshaus:

Melonen

Echter Mehltau der Kürbisgewächse

Falscher Mehltau der Kürbisgewächse

Konzentration: 0.1 %

Aufwandmenge: 1 l/ha

Wartefrist: 3 Tage

2, 11

G Karotten

Alternaria-Möhrenschwärze

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 14

Knoblauch

Schalotten

Zwiebeln

Falscher Mehltau der Zwiebel

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 14

G Knollenfenchel

Cercospora- und Ramularia-

Blattfleckenkrankheiten

Falscher Mehltau der Doldenblütler

Aufwandmenge: 1 l/ha

Wartefrist: 1 Woche(n)

2, 14

G Kohlrabi

Alternaria-Kohlschwärze

Aufwandmenge: 1 l/ha

2, 14

A

Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

Speisekohlrüben

Wartefrist: 2 Woche(n)

Kürbisgewächse

(Cucurbitaceae)

Echter Mehltau der Kürbisgewächse

Falscher Mehltau der Kürbisgewächse

Aufwandmenge: 1 l/ha

Wartefrist: 3 Woche(n)

2, 11

G Lauch

Alternaria-Purpurfleckenkrankheit

Papierfleckenkrankheit des Lauchs

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 14

G Mangold

Cercospora- und Ramularia-

Blattfleckenkrankheiten

Aufwandmenge: 1 l/ha

Wartefrist: 3 Woche(n)

2, 12, 14

Meerrettich

Radies

Rettich

Alternaria-Kohlschwärze

Falscher Mehltau der

Kreuzblütengewächse

Weisser Rost

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

Anwendung: Ab Stadium

BBCH 10 (Keimblätter

voll entfaltet).

2, 11, 12

G Petersilie

Septoria-Blattfleckenkrankheit der

Petersilie

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 14

G Rucola

Blattfleckenpilze

Falscher Mehltau der

Kreuzblütengewächse

Teilwirkung:

Graufäule (Botrytis cinerea)

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 11

G Salate (Asteraceae)

Falscher Mehltau des Salats

Rhizoctonia-Fäule des Salats

Teilwirkung:

Graufäule (Botrytis cinerea)

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 11

G Schnittlauch

Alternaria spp.

Rost auf Zwiebel-Arten

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 3, 12

G Sellerie

Septoria-Blattfleckenkrankheit des

Selleries

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 14

G Spargel

Blattschwärze der Spargel

Spargelrost

Aufwandmenge: 1 l/ha

Anwendung: In

Junganlagen oder in

Ertragsanlagen nach der

Ernte.

2, 6

G Tomaten

Alternaria-Dürrfleckenkrankheit

Echter Mehltau der Solanaceae

Kraut- und Fruchtfäule

Konzentration: 0.1 %

Wartefrist: 3 Tage

2, 5, 14

F Eiweisserbse

Brennfleckenkrankheit der Erbse

Falscher Mehltau der Erbse

Graufäule (Botrytis cinerea)

Aufwandmenge: 1 l/ha

Wartefrist: 2 Woche(n)

2, 11, 15

A

Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

F Gerste

Echter Mehltau des Getreides

Netzfleckenkrankheit der Gerste

Rhynchosporium-Blattfleckenkrankheit

Aufwandmenge: 0.4 l/ha

Anwendung: Stadium 31-

51 (BBCH).

2, 16, 17

F Gerste

Echter Mehltau des Getreides

Netzfleckenkrankheit der Gerste

Rhynchosporium-Blattfleckenkrankheit

Zwergrost der Gerste

Aufwandmenge: 1 l/ha

Anwendung: Stadium 31-

51 (BBCH).

2, 17

F Hopfen

Falscher Mehltau des Hopfens

Teilwirkung:

Echter Mehltau des Hopfens

Konzentration: 0.1 %

Wartefrist: 4 Woche(n)

2, 18, 19,

20, 21

F Kartoffeln

Alternaria-Dürrfleckenkrankheit

Kraut- und Knollenfäule

Aufwandmenge: 0.75 l/ha

Wartefrist: 1 Woche(n)

Anwendung:

Behandlungen bei vollem

Krautwachstum.

2, 14, 22,

F Lupinen

Anthraknose der Lupine

Aufwandmenge: 0.8 l/ha

Wartefrist: 42 Tage

2, 11, 12,

F Raps

Sclerotinia-Fäule

Aufwandmenge: 1 l/ha

Anwendung: Stadium 61-

65 (BBCH).

2, 17

F Roggen

Braunrost

Aufwandmenge: 0.4 l/ha

Anwendung: Stadium 37-

61 (BBCH).

2, 16, 17

F Roggen

Braunrost

Aufwandmenge: 1 l/ha

Anwendung: Stadium 37-

61 (BBCH).

2, 17

F Triticale

Braunrost

Gelbrost

Septoria-Blattdürre (S. tritici oder S.

nodorum)

Aufwandmenge: 0.4 l/ha

Anwendung: Stadium 31-

61 (BBCH).

2, 16, 17

F Triticale

Rhynchosporium-Blattfleckenkrankheit

Aufwandmenge: 1 l/ha

Anwendung: Stadium 37-

61 (BBCH).

2, 17

F Trockenreis

Braunfleckigkeit des Reises

Reisbräune

Aufwandmenge: 1 l/ha

Wartefrist: 4 Woche(n)

Anwendung: Stadium 24-

55 (BBCH).

2, 12, 25

F Weizen

Braunrost

Echter Mehltau des Getreides

Gelbrost

Aufwandmenge: 0.4 l/ha

Anwendung: Stadium 31-

2, 16, 17

A

Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

Septoria-Spelzenbräune (S. nodorum)

61 (BBCH).

F Weizen

Braunrost

Echter Mehltau des Getreides

Gelbrost

Septoria-Blattdürre (S. tritici oder S.

nodorum)

Septoria-Spelzenbräune (S. nodorum)

Aufwandmenge: 1 l/ha

Anwendung: Stadium 31-

61 (BBCH).

2, 17

Z Blaudistel

Blattfleckenkrankheit der Blaudisteln

Konzentration: 0.1 %

2, 14, 26

Z Chrysantheme

Echte Mehltaupilze der Zierpflanzen

Teilwirkung:

Graufäule (Botrytis cinerea)

Konzentration: 0.1 %

2, 14, 26

Liliengewächse

(Zierpflanzen)

Rostpilze der Zierpflanzen

Teilwirkung:

Graufäule (Botrytis cinerea)

Konzentration: 0.1 %

2, 14, 26

Z Nelken

Echte Mehltaupilze der Zierpflanzen

Rostpilze der Zierpflanzen

Teilwirkung:

Graufäule (Botrytis cinerea)

Konzentration: 0.1 %

2, 14, 26

Z Rosen

Echter Mehltau der Rosen

Rost der Rose

Teilwirkung:

Graufäule (Botrytis cinerea)

Konzentration: 0.1 %

2, 3, 26

Z Zier- und Sportrasen

Blattfleckenkrankheit

Fusarium culmorum

Gaeumannomyces graminis var. avenae

(Rasen)

Ophiosphaerella herpotricha

Pythium spp.

Rasenanthracnose

Rhizoctonia-Krankheiten des Rasens

Rotfadenkrankheit des Rasens

Schneeschimmel

Sommerflecken

Aufwandmenge: 1 l/ha

2, 6, 27

Auflagen und Bemerkungen:

Die angegebene Aufwandmenge bezieht sich auf Stadium "Vollblüte bis Beginn Rotfärbung der

Früchte", 4 Pflanzen pro m² sowie eine Referenzbrühmenge von 1000 l/ha.

Ansetzen der Spritzbrühe: Schutzhandschuhe tragen.

SPa 1: Zur Vermeidung einer Resistenzbildung maximal 3 Behandlungen pro Kultur und Jahr mit

Produkten aus der Wirkstoffgruppe FRAC C3 (u.a. Strobilurine).

Die angegebene Aufwandmenge bezieht sich auf Stadium "50 - 90% der Blütenstände mit

sichtbaren Früchten" sowie eine Referenzbrühmenge von 1000 l/ha.

SPe 3: Zum Schutz von Gewässerorganismen vor den Folgen von Drift eine unbehandelte

Pufferzone von 6 m zu Oberflächengewässern einhalten. Diese Distanz kann beim Einsatz von

driftreduzierenden Massnahmen gemäss den Weisungen des BLW reduziert werden.

SPa 1: Zur Vermeidung einer Resistenzbildung maximal 3 Behandlungen pro Parzelle und Jahr

mit Produkten aus der Wirkstoffgruppe FRAC C3 (u.a. Strobilurine).

Für Sommerhimbeeren bezieht sich die angegebene Aufwandmenge auf Stadium "Erste Blüten bis

etwa 50% der Blüten offen" sowie eine Referenzbrühmenge von 1000 l/ha. Für Herbsthimbeeren

bezieht sich die Aufwandmenge auf eine Heckenhöhe von 150 - 170 cm sowie eine

Referenzbrühmenge von 1000 l/ha.

Für Brombeeren bezieht sich die angegebene Aufwandmenge auf Stadium "Erste Blüten bis etwa

50% der Blüten offen" sowie eine Referenzbrühmenge von 1000 l/ha.

Die angegebene Aufwandmenge bezieht sich auf ein Baumvolumen von 10'000 m³ pro ha.

10.SPe 3: Zum Schutz von Gewässerorganismen vor den Folgen von Drift eine unbehandelte

Pufferzone von 20 m zu Oberflächengewässern einhalten. Diese Distanz kann beim Einsatz von

driftreduzierenden Massnahmen gemäss den Weisungen des BLW reduziert werden.

11.SPa 1: Zur Vermeidung einer Resistenzbildung maximal 2 Behandlungen pro Kultur mit

Produkten aus der Wirkstoffgruppe FRAC C3 (u.a. Strobilurine).

12.Bewilligt als geringfügige Verwendung nach Art. 35 PSMV (minor use).

13.Maximal 1 Behandlung pro Kultur mit diesem Produkt oder einem anderen Produkt, das diesen

Wirkstoff enthält.

14.SPa 1: Zur Vermeidung einer Resistenzbildung maximal 3 Behandlungen pro Kultur mit

Produkten aus der Wirkstoffgruppe FRAC C3 (u.a. Strobilurine).

15.Behandlungen im Abstand von 8-12 Tagen.

16.In Tankmischung mit 1.2 l/ha Sirocco (60 g/l Metconazole).

17.Maximal 1 Behandlung pro Kultur.

18.Vorsicht: Resistenzgefahr! Produkt im Wechsel mit Produkten anderer Wirkstoffgruppen

einsetzen.

19.Die maximale Aufwandmenge von 1.6 l/ha pro Applikation darf nicht überschritten werden.

20.SPe 3: Zum Schutz von Gewässerorganismen vor den Folgen von Drift eine unbehandelte

Pufferzone von 20 m zu Oberflächengewässern einhalten. Zum Schutz vor den Folgen einer

Abschwemmung eine mit einer geschlossenen Pflanzendecke bewachsene Pufferzone von

mindestens 6 m einhalten. Reduktion der Distanz aufgrund von Drift und Ausnahmen gemäss den

Weisungen des BLW.

21.SPa 1: Zur Vermeidung einer Resistenzbildung maximal 2 Behandlungen pro Parzelle und Jahr

mit Produkten aus der Wirkstoffgruppe FRAC C3 (u.a. Strobilurine).

22.Behandlungen im Abstand von 7-10 Tagen.

23.Bei Frühkartoffeln 2 Wochen Wartefrist.

24.Behandlungen im Abstand von 14 Tagen.

25.Maximal 2 Behandlungen pro Kultur im Abstand von 10-14 Tagen.

26.SPe 3: Zum Schutz von Gewässerorganismen vor den Folgen von Drift eine unbehandelte

Pufferzone von 6 m zu Oberflächengewässern einhalten. Zum Schutz vor den Folgen einer

Abschwemmung eine mit einer geschlossenen Pflanzendecke bewachsene Pufferzone von

mindestens 6 m einhalten. Reduktion der Distanz aufgrund von Drift und Ausnahmen gemäss den

Weisungen des BLW.

27.SPe 3: Zum Schutz von Gewässerorganismen vor den Folgen einer Abschwemmung eine mit

einer geschlossenen Pflanzendecke bewachsene unbehandelte Pufferzone von mindestens 6 m zu

Oberflächengewässern einhalten. Ausnahmen sind in den Weisungen des BLW festgelegt.

Gefahrenkennzeichnungen:

Es gilt die Einstufung und Kennzeichnung der ausländischen Originaletikette..

Zusätzliche Schweizerische Gefahrenkennzeichnungen:

SP 1 Mittel und/oder dessen Behälter nicht in Gewässer gelangen lassen.

SPe 2 Zum Schutz von Grundwasser nicht in Grundwasserschutzzonen (S2) ausbringen.

Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erwähnung eines Produktes,

Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im

Verkauf befindet.

22-1-2019

SIGMA Animal Disease Data Model: A comprehensive approach for the collection of standardised data on animal diseases

SIGMA Animal Disease Data Model: A comprehensive approach for the collection of standardised data on animal diseases

Published on: Mon, 21 Jan 2019 The European Commission is routinely asking EFSA for scientific and technical support in the epidemiological analysis of animal disease outbreaks (i.e. African swine fever, lumpy skin disease and avian influenza) and to report or assess surveillance data (i.e. Echinococcus multilocularis and avian influenza). For this purpose, EFSA has over the last years carried out several data collections and gathered specific information on outbreaks, surveillance activities and concer...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-1-2019

Succinate dehydrogenase inhibitor (SDHI) fungicides: ANSES presents the results of its expert appraisal

Succinate dehydrogenase inhibitor (SDHI) fungicides: ANSES presents the results of its expert appraisal

A group of scientists recently warned of the potential health risks of using succinate dehydrogenase inhibitor (SDHI) fungicides in agriculture. In this context, ANSES asked a group of independent experts to examine the hypotheses put forward by these scientists. The experts considered all the available scientific data in order to determine, in particular, whether this evidence constituted a health alert.

France - Agence Nationale du Médicament Vétérinaire

19-1-2019

Ottogi America, Inc. Issues Allergy Alert on Undeclared Egg in Products

Ottogi America, Inc. Issues Allergy Alert on Undeclared Egg in Products

Ottogi America, Inc. announced today it is recalling below 21 items due to a possibility of containing egg ingredient undeclared on the packages. People who have an allergy or severe sensitivity to eggs run the risk of serious or life-threatening allergic reaction of they consume these products.

FDA - U.S. Food and Drug Administration

18-1-2019

Publication of scientific data from EU-coordinated monitoring programmes and surveys

Publication of scientific data from EU-coordinated monitoring programmes and surveys

Published on: Thu, 17 Jan 2019 Open government data are about wide and free availability of public information created or collected by public entities. The International Open Data Charter and Findable, Accessible, Interoperable And Reusable Data (FAIR) data principles were selected as the guiding principles for the development of this report. A review of open data maturity reports indicated that most of the EU28+ are making significant progress in open government data, however there are different levels...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Outcome of the public consultation on the draft statement on genotoxicity assessment of chemical mixtures

Outcome of the public consultation on the draft statement on genotoxicity assessment of chemical mixtures

Published on: Wed, 16 Jan 2019 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the genotoxicity assessment of chemical mixtures. The draft statement was prepared by a dedicated working group of the Scientific Committee and endorsed by the Scientific Committee for public consultation at its 89th plenary meeting of 28‐29 May 2018. The public consultation for this document was open from 26 June until 9 ...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Outcome of the Public Consultation on the draft Guidance on Communication of Uncertainty in Scientific Assessments

Outcome of the Public Consultation on the draft Guidance on Communication of Uncertainty in Scientific Assessments

Published on: Wed, 16 Jan 2019 The first strategic objective of EFSA's strategy 2020 ‘Trusted science for safe food’ is the prioritisation of public and stakeholder engagement in the development of scientific assessment. To achieve this, objective public consultations are a key step for such a strategic framework. The draft Guidance document on communication of uncertainty underwent a web‐based public consultation from 4 May to 24 June 2018. The document provides guidance for communicators on how to com...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Published on: Wed, 16 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of two compounds belonging to chemical group 20 (aliphatic and aromatic mono‐ and di‐thiols and mono‐, di‐, tri‐, and polysulfides with or without additional oxygenated functional groups). 8‐Mercapto‐p‐menthan‐3‐one [12.038] and p‐menth‐1‐ene‐8‐thiol [12.085] are currently ...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Genotoxicity assessment of chemical mixtures

Genotoxicity assessment of chemical mixtures

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Guidance on Communication of Uncertainty in Scientific Assessments

Guidance on Communication of Uncertainty in Scientific Assessments

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Published on: Mon, 14 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of B‐Act® when used in feed for turkeys for fattening, reared for breeding and minor poultry species for fattening or raised for laying. B‐Act® is a preparation containing viable spores of a Bacillus licheniformis strain. This species is considered by EFSA to be suitable for the qua...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

RXBAR Recalls Certain Varieties of Bars Due to a Potential Undeclared Peanut Allergen

RXBAR Recalls Certain Varieties of Bars Due to a Potential Undeclared Peanut Allergen

RXBAR is voluntarily recalling certain varieties of bars because they may contain undeclared peanuts. People who have peanut allergies run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

15-1-2019

Assessment of genetically modified soybean A2704‐12 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐009)

Assessment of genetically modified soybean A2704‐12 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐009)

Published on: Mon, 14 Jan 2019 Following the submission of application EFSA‐GMO‐RX‐009 under Regulation (EC) No 1829/2003 from Bayer CropScience N.V., the Panel on Genetically Modified Organisms of the European Food Safety Authority was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the herbicide‐tolerant genetically modified soybean A2704‐12, for food and feed uses, import and processing, excluding cultivation within th...

Europe - EFSA - European Food Safety Authority EFSA Journal

15-1-2019

EFSA's activities on emerging risks in 2017

EFSA's activities on emerging risks in 2017

Published on: Mon, 14 Jan 2019 The main objectives of EFSA's activities on emerging risks are: (i) to carry out activities to identify emerging risks in the areas within the remit of EFSA; and (ii) to develop and improve emerging risk identification methodologies and approaches. The current technical report summarises the activities of all groups involved in the emerging risk identification procedure, the issues identified in the course of 2017, a description of methodologies being developed and collabo...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Scientific Opinion on Flavouring Group Evaluation 208 Revision 3 (FGE.208Rev3): consideration of genotoxicity data on alicyclic aldehydes with α,β‐unsaturation in ring/side‐chain and precursors from chemical subgroup 2.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 208 Revision 3 (FGE.208Rev3): consideration of genotoxicity data on alicyclic aldehydes with α,β‐unsaturation in ring/side‐chain and precursors from chemical subgroup 2.2 of FGE.19

Published on: Fri, 11 Jan 2019 The EFSA Panel on Food Additives and Flavourings was requested to evaluate the genotoxic potential of flavouring substances from subgroup 2.2 of FGE.19 in the Flavouring Group Evaluation 208 Revision 3 (FGE.208Rev3). In FGE.208Rev1, the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) evaluated genotoxicity studies on the representative substance p‐mentha‐1,8‐dien‐7‐al [FL‐no: 05.117], which was found to be genotoxic in vivo. The Panel conclu...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety and efficacy of Lactobacillus reuteri NBF‐2 (DSM 32264) as a feed additive for cats

Safety and efficacy of Lactobacillus reuteri NBF‐2 (DSM 32264) as a feed additive for cats

Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Lactobacillus reuteri NBF‐2 when used in feed for cats at a minimum dose of 6 × 109 colony forming units (CFU) per animal and day. The additive is a preparation of viable cells of L. reuteri DSM 32264. This species is considered by EFSA to be suitable for the qualified presum...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety and efficacy of Lactobacillus reuteri NBF‐1 (DSM 32203) as a feed additive for dogs

Safety and efficacy of Lactobacillus reuteri NBF‐1 (DSM 32203) as a feed additive for dogs

Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Lactobacillus reuteri NBF‐1 when used in feed for dogs at a minimum dose of 6 × 109 colony forming units (CFU) per animal and day. The additive is a preparation of viable cells of L. reuteri DSM 32203. This species is considered by the European Food Safety Authority to be sui...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety and efficacy of HOSTAZYM® X (endo‐1,4‐beta‐xylanase) as a feed additive for rabbits for fattening

Safety and efficacy of HOSTAZYM® X (endo‐1,4‐beta‐xylanase) as a feed additive for rabbits for fattening

Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for rabbits for fattening. HOSTAZYM® X contains endo‐1,4‐beta‐xylanase produced by a strain of Trichoderma citrinoviride and is available in liquid and solid formulations. It is authorised as a feed additive for chickens for fattening, turkeys f...

Europe - EFSA - European Food Safety Authority EFSA Journal

4-1-2019

Olde York Potato Chips Issues Allergy Alert on Undeclared Milk in One Lot of Clancy's Wavy Potato Chips 10 Oz

Olde York Potato Chips Issues Allergy Alert on Undeclared Milk in One Lot of Clancy's Wavy Potato Chips 10 Oz

Olde York Potato Chips of Brampton, Ontario is recalling Clancy's Wavy Potato Chips 10 oz (UPC 0 41498 16306 8) with the specific lot code BEST If Used By FEB 22 19 1A6 because they may contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products. No other lot codes and no other products are involved in this action.

FDA - U.S. Food and Drug Administration

4-1-2019

Bee health

Bee health

For several years now, a phenomenon resulting in the weakening and mortality of bee colonies has been seen in many countries. In this context, the impact of various factors that may act alone or in combination on the health of bee colonies (infectious and parasitic diseases, stress related to changes in food resources, plant protection products, climate conditions, etc.) has regularly been demonstrated through different scientific studies. Below is an update on this issue and details of the Agency's work.

France - Agence Nationale du Médicament Vétérinaire

3-1-2019

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Due to a potential manufacturing defect the lights may overheat, posing a burn and fire hazard.

Health Canada

21-12-2018

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, LLC of Eden Prairie, MN is recalling 10 oz Nutty Choco Pop Gift Box, 50 oz. Holiday Crowd Pleaser and 50 oz. Crowd Pleaser, because it may contain undeclared Almond and Cashew Tree Nut. People who have an allergy or severe sensitivity to Almonds and Cashews run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

21-12-2018

FDA approves new treatment for adult patients with rare, life-threatening blood disease

FDA approves new treatment for adult patients with rare, life-threatening blood disease

The FDA approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.

FDA - U.S. Food and Drug Administration

20-12-2018

Workshop on Avian Influenza

Workshop on Avian Influenza

Published on: Wed, 19 Dec 2018 Since September 2017, EFSA has been providing ongoing scientific and technical support to the European Commission and Member States (MSs) in the collection, collation, and analysis of epidemiological data relevant to the monitoring of avian influenza (AI) viruses in Europe and third countries. From 2019 onwards, EFSA will also be responsible for collecting, collating, and analysing the data gathered by MSs via their surveillance programmes in poultry and wild birds. To eff...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-12-2018

Scientific assistance to assess the detoxification process for dioxins and PCBs in sunflower cake by hexane extraction

Scientific assistance to assess the detoxification process for dioxins and PCBs in sunflower cake by hexane extraction

Published on: Wed, 19 Dec 2018 EFSA was requested to provide scientific assistance to the European Commission on a detoxification process for dioxins and PCBs from sunflower cake by hexane extraction in an emergency situation, as specified in Article 7 of Commission Regulation (EU) 2015/786. The process entails hexane extraction of sunflower oil from the cake to remove dioxins (PCDDs and PCDFs) as well as DL- and NDL-PCBs. The data provided by the applicant were assessed with respect to the efficacy of ...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-12-2018

Pest categorisation of Gymnosporangium spp. (non‐EU)

Pest categorisation of Gymnosporangium spp. (non‐EU)

Published on: Wed, 19 Dec 2018 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Gymnosporangium spp. (non‐EU), a well‐defined and distinguishable group of fungal plant pathogens of the family Pucciniaceae affecting woody species. Many different Gymnosporangium species are recognised, of which at least 14 species are considered not to be native in the European Union. All the non‐EU Gymnosporangium species are not known to be present in th...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-12-2018

Outcome of the consultation with Member States, the applicant and EFSA on the pesticide risk assessment for mesotrione in light of confirmatory data

Outcome of the consultation with Member States, the applicant and EFSA on the pesticide risk assessment for mesotrione in light of confirmatory data

Published on: Wed, 19 Dec 2018 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the risk assessment for an active substance in light of confirmatory data requested following approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009. In this context EFSA's scientific views on the specific points raised during the commenting phase conducted with Member States, the applican...

Europe - EFSA - European Food Safety Authority EFSA Journal

19-12-2018

Lifetone Technology, Inc. recalls Lifetone HLAC151 Bedside Fire Alarm and Clock

Lifetone Technology, Inc. recalls Lifetone HLAC151 Bedside Fire Alarm and Clock

The bedside fire alarm and clock can fail to operate and fully alert consumers to a fire.

Health Canada

19-12-2018

Safety and efficacy of vitamin B2 (riboflavin 5′‐phosphate ester monosodium salt) for all animal species when used in water for drinking

Safety and efficacy of vitamin B2 (riboflavin 5′‐phosphate ester monosodium salt) for all animal species when used in water for drinking

Published on: Tue, 18 Dec 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on vitamin B2 in the form of riboflavin 5′‐phosphate ester monosodium salt as an additive for all animal species for use in water for drinking. The additive under assessment is obtained from ■■■■■ a source of riboflavin produced by Ashbya gossypii. No information was provided on the identity and character...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-12-2018

Atherstone Foods Inc Issues Allergy Alert on Undeclared Soy in “Greens and Grains Hummus and Quinoa Tabouleh Wrap”

Atherstone Foods Inc Issues Allergy Alert on Undeclared Soy in “Greens and Grains Hummus and Quinoa Tabouleh Wrap”

ATHERSTONE FOODS INC of Richmond, CA is recalling 14.6 ounce (414g) Greens and Grains Hummus and Quinoa Tabouleh Wrap, because it may contain undeclared soy, people who have an allergy or severe sensitivity to soy run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

15-12-2018

Annual report of the Scientific Network on Microbiological Risk Assessment 2018

Annual report of the Scientific Network on Microbiological Risk Assessment 2018

Published on: Fri, 14 Dec 2018 Among the tasks of EFSA, according to its founding regulation (Regulation (EC) No 178/2002), there is the establishment of a system of Networks of organisations operating in the fields within EFSA's mission, the objective being to facilitate a scientific cooperation framework by the coordination of activities, the exchange of information, the development and implementation of joint projects, the exchange of expertise and best practices. Additionally, the EFSA Science Strat...

Europe - EFSA - European Food Safety Authority Publications

15-12-2018

Annual Report of the Scientific Network on BSE‐TSE 2018

Annual Report of the Scientific Network on BSE‐TSE 2018

Published on: Fri, 14 Dec 2018 The EFSA Scientific Network on bovine spongiform encephalopathies and other transmissible spongiform encephalopathies (BSE‐TSE) held its 13th meeting on 15‐16 October 2018 in Parma. The meeting served as an opportunity to exchange scientific information on BSE‐TSE related issues among EU Member States, countries from the European Free Trade Association (EFTA), EFSA, the European Commission and ad hocparticipants. In this occasion, ad hoc representation included the World A...

Europe - EFSA - European Food Safety Authority Publications

14-12-2018

Response to comments on the Scientific Opinion on the scientific substantiation of a health claim related to Symbiosal® and lowering of blood pressure and reduced risk of hypertension pursuant to Article 14 of Regulation (EC) No 1924/2006

Response to comments on the Scientific Opinion on the scientific substantiation of a health claim related to Symbiosal® and lowering of blood pressure and reduced risk of hypertension pursuant to Article 14 of Regulation (EC) No 1924/2006

Published on: Thu, 13 Dec 2018 Following a request from the European Commission, EFSA was asked to review the comments received on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to Symbiosal® and lowering of blood pressure and reduced risk of hypertension pursuant to Article 14 of Regulation (EC) No 1924/2006. Comments originating from the applicant (Han‐Biotech GmbH) were submitted to EFSA via the E...

Europe - EFSA - European Food Safety Authority Publications

14-12-2018

Statement on the safety of d‐ribose

Statement on the safety of d‐ribose

Published on: Thu, 13 Dec 2018 In 2018, the EFSA NDA Panel adopted the Scientific Opinion on the safety of d‐ribose as a novel food pursuant to Regulation (EU) 2015/2283 when used in a variety of food, concluding that d‐ribose is safe for the general population at intake levels up to 36 mg/kg body weight (bw) per day, but that its safety at the intended uses and use levels as proposed by the applicant could not be established. Following a request from the European Commission, the EFSA NDA Panel was aske...

Europe - EFSA - European Food Safety Authority Publications

12-12-2018

Del Monte Foods Announces Limited Recall of Canned Fiesta Corn Seasoned with Red & Green Peppers Due to Under Processing

Del Monte Foods Announces Limited Recall of Canned Fiesta Corn Seasoned with Red & Green Peppers Due to Under Processing

Del Monte Foods Inc. announced a recall of 64,242 cases of FIESTA CORN Seasoned with Red & Green Peppers due to under-processing. These deviations were part of the commercial sterilization process and could result in contamination by spoilage organisms or pathogens, which could lead to life-threatening illness if consumed. It is important to note that there have been no reports of illness associated with these products to date. No other production codes or products are affected by this recall.

FDA - U.S. Food and Drug Administration

21-1-2019


Nitrofurantoin, nifurtoinol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002174/201802

Nitrofurantoin, nifurtoinol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002174/201802

Nitrofurantoin, nifurtoinol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002174/201802

Europe - EMA - European Medicines Agency

21-1-2019


Ciprofloxacin (systemic use):  CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000775/201801

Ciprofloxacin (systemic use): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000775/201801

Ciprofloxacin (systemic use): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000775/201801

Europe - EMA - European Medicines Agency

14-1-2019


Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobials

Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobials

Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobials

Europe - EMA - European Medicines Agency

10-1-2019


BCG vaccine (freeze-dried): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00000304/201803

BCG vaccine (freeze-dried): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000304/201803

BCG vaccine (freeze-dried): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000304/201803

Europe - EMA - European Medicines Agency

10-1-2019


Lorazepam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001909/201801

Lorazepam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001909/201801

Lorazepam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001909/201801

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Europe - EMA - European Medicines Agency

19-12-2018

The Breakthrough Devices Program’s goal is to provide patients and health care providers with timely access to devices that treat or diagnose a life-threatening or irreversibly debilitating condition.

The Breakthrough Devices Program’s goal is to provide patients and health care providers with timely access to devices that treat or diagnose a life-threatening or irreversibly debilitating condition.

The Breakthrough Devices Program’s goal is to provide patients and health care providers with timely access to devices that treat or diagnose a life-threatening or irreversibly debilitating condition.

FDA - U.S. Food and Drug Administration

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Europe - EMA - European Medicines Agency